Z
Zetagen Therapeutics
Biopharmaceutical company dedicated to driving breakthrough innovation in the treatment of metastatic bone cancers and osteologic interventions
About Zetagen Therapeutics
Zetagen is a biotechnology company specializing in the development of osteoinductive platform technologies aimed at promoting bone growth. The company operates in the orthopedic market, focusing on creating products that activate a novel molecular pathway to stimulate bone regeneration. Zetagen's innovative approach has the potential to revolutionize the treatment of bone-related injuries, procedures, and diseases, offering better, safer, and more cost-effective solutions for patients, healthcare providers, and payors.
The company's primary clients include orthopedic surgeons, hospitals, and healthcare systems that require advanced solutions for bone repair and regeneration. Zetagen's business model revolves around the commercialization of its proprietary small molecule-based technology, generating revenue through product sales and potential licensing agreements.
Zetagen's leadership team, led by CEO Joe Loy, brings extensive experience in the spine and orthopedic industries, with a proven track record of driving growth and successful acquisitions. The company is committed to continuous learning and innovation, striving to deliver optimal therapeutic solutions that benefit patients, investors, and society.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | Jan 2026 | $0 | — | Excell Partners | ↗ |
| SERIES B✓Equity / VC | Nov 2025 | $13M | $52M | JSTAR Capital Investments | ↗ |
Growth signals
Latest recorded traffic for Zetagen Therapeutics is 1.5K monthly website visits, down 25% over the last three months. Zetagen Therapeutics's team grew 12.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Zetagen Therapeutics in the Syracuse ecosystem
The Zetagen Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
MedTech Innovator
National Cancer Institute (NCI)
Series A4 investors entered at this stage
National Institutes of Health
Consolidated Investment Group
New York Ventures
JSTAR Capital Investments
Series B and later1 investor entered at this stage
Excell Partners
Other known investors3 additional known investors
State University of New York
Central New York Biotech Accelerator
Small Business Innovation Research
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Zetagen Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Zetagen Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










